Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.12 USD
+0.76 (55.88%)
Updated Apr 30, 2024 03:59 PM ET
After-Market: $1.95 -0.17 (-8.02%) 6:18 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYCC 2.12 +0.76(55.88%)
Will CYCC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYCC
New Strong Buy Stocks for October 17th
Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
Other News for CYCC
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals among healthcare movers
Why Is Coursera (COUR) Stock Down 16% Today?
Why Is Medifast (MED) Stock Down 20% Today?